Mar 08,2017

Virta Health Launches to Reverse Type 2 Diabetes as New Study Demonstrates Reversal Possible Without Surgery

Virta Health, a new company founded by a team of physicians, scientists, and technologists trained at Stanford, MIT, and Harvard, launches today with a bold mission to reverse type 2 diabetes—a chronic, progressive condition that affects more than 29 million Americans and 415 million people globally. The company’s debut comes on the heels of a new peer-reviewed study that demonstrates Virta was successful in reversing type 2 diabetes in half of its clinical trial patients and eliminating or reducing insulin in 87 percent of patients in just 10 weeks.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 08,2017

Tandem Diabetes Care Announces Filing of Registration Statement for Proposed Follow-on Public Offering of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of approximately $50 million of its common stock.

View Analyst & Ambassador Comments
Go to original news
Mar 08,2017

Tandem Diabetes Care Announces Plans for Improved Infusion Set Connector Developed from Customer Feedback

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced plans to implement a new infusion set connector for Tandem insulin pump cartridges and infusion sets, the t:lock™ Connector. Consistent with the philosophy followed for the development of all of Tandem's products, the t:lock Connector was designed based on direct customer feedback related to the process for filling the infusion set with insulin.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 23,2017

Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $1.25 per share. The gross proceeds to Tandem from this offering are expected to be $22.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tandem.

View Analyst & Ambassador Comments
Go to original news
Mar 24,2017

Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy

Dexcom is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile system, the only therapeutic CGM under this CMS classification. People covered by Medicare who have either Type 1 or Type 2 diabetes and intensively manage their insulin will now be able to obtain reimbursement.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 28,2017

BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management

Since 2013, The BD Helping Build Healthy Communities program has donated $8.6 million in cash and products to support diabetes care management for uninsured and under-insured Americans and to provide grants to community health centers for innovative approaches to the treatment of multiple diseases, including diabetes, HIV/AIDS and cervical cancer.

View Analyst & Ambassador Comments
Go to original news
Mar 31,2017

One Drop demonstrates dramatic improvements in A1c among people with diabetes using the One Drop | Mobile platform

One Drop today announced findings from a retrospective study demonstrating that One Drop | Mobile app users report a substantial improvement in glycemic control, reducing A1c by 1.0 percentage point after only 2 to 12 months of using One Drop | Mobile.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 06,2017

Sanofi gets FDA clearance for insulin dose calculator app

Following in the footsteps of Eli Lilly and Roche, Sanofi has quietly received FDA clearance for a smartphone app with a built-in insulin dose calculator. According to FDA documents, the app, cleared at the end of March, is called My Dose Coach.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 11,2017

JAMA study shows telemedicine can improve screening access, efficiency for diabetes-caused blindness in LA County safety net populations

In an article published in the journal JAMA Internal Medicine, researchers describe how the two-year collaboration using Safety Net Connect’s eConsult platform resulted in more screenings, shorter wait times and fewer in-person specialty care visits. By deploying Safety Net Connect’s eConsult system to a group of 21,222 patients, the wait times for screens decreased by almost 90 percent, and overall screening rates for diabetic retinopathy increased 16 percent.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Apr 11,2017

Merck, Amazon challenge developers to build Alexa apps for diabetes

Amazon Web Services and Merck announced a developer competition on Monday to that plans to harness artificial intelligence for diabetics. Dubbed the Alexa Diabetes Challenge, and powered by Luminary Labs, the contest aims to incent upstarts and individual developers to create apps that harness Amazon’s Alexa voice-enabled technologies particularly for patients recently diagnosed with Type 2 diabetes.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES